AzTrials
AzTrials

Idiopathic Pulmonary FibrosisTOUPIENCT03944928

ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution

An observational study of Idiopathic Pulmonary Fibrosis, run by University Hospital, Tours at 2 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Idiopathic pulmonary fibrosis (IPF) is one of the most common chronic idiopathic fibrotic interstitial lung disease (ILD). IPF is an evolving disease that requires regular follow-up through clinical examination, respiratory functional investigations and thoracic CT. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Idiopathic Pulmonary Fibrosis
What is being tested?
Lung ultrasound
How many people
30 participants
Where
2 sitesFrance
Study dates
11 Jun 2019to 9 Sep 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient with idiopathic pulmonary fibrosis

Who may be able to join

  • more than 18 years-old
  • diagnosis of IPF validated in a multidisciplinary consultation meeting (RCP) according to French recommendations

Who cannot join

  • pregnant or lactating women
  • exacerbation of fibrosis on inclusion
  • right or left heart aggravation on inclusion
  • evolutive pulmonary infectious disease
  • other forms of diffuse interstitial lung disease
  • opposition to the data collection

Trial locations and contacts

2 sites in 1 country.

France2 sites
  • CHR Orleans

    Orléans, 45067

  • Pulmonology Department, University Hospital, Tours

    Tours, 37044

Other trials in France

About this study

Idiopathic pulmonary fibrosis (IPF) is one of the most common chronic idiopathic fibrotic interstitial lung disease (ILD). IPF is an evolving disease that requires regular follow-up through clinical examination, respiratory functional investigations and thoracic CT. Thoracic CT is necessary for the follow-up, usually performed yearly, and in case of deterioration of respiratory function. The disadvantages to its realization are the repeated irradiation, the cost, the accessibility, and sometimes the difficulties of realization related to the supine position.

Several signs of thoracic ultrasound have been described in ILD, including the number of B lines, the irregularity of the pleural line, and the thickening of the pleural line. Cross-sectional studies have correlated the intensity of these signs with the severity of fibrosis lesions on chest CT in patients with ILD, including IPF. However, no studies have prospectively described the evolution of ultrasound signs in the same IPF patient, or their correlation to clinical, functional and CT scan evolution.

Read more

The hypothesis is that thoracic ultrasound is a relevant tool to highlight the evolution of pulmonary lesions in IPF.

The main objective is to show with thoracic ultrasound an increase in one or more of the ultrasound signs: line B score, pleural line irregularity score, and pleural line thickness during the follow-up of patient with IPF.

The study will enroll patients with a validated diagnosis of IPF in a multidisciplinary staff. At each follow-up visit, patients will have a clinical examination, pulmonary functional test and thoracic ultrasound. The CT data collected will include the last thoracic CT performed in the 3 months before the inclusion and those performed during the patient's participation. The presence, location and severity of ultrasound signs, will be recorded for each patient during successive reassessments and correlation to clinical, functional and CT scan evolution will be made.

This study will add significant knowledge in the study of ultrasound signs evolution in patients with IPF. If there is a correlation with the clinical or CT scores, it will be possible to carry over the realization of the CTs to limit the irradiation of the patients. Conversely, early detection of worsening ultrasound signs may lead to faster therapeutic adjustments to limit the extent of irreversible fibrotic lesions.

Read the detailed description
  • Clinical and scientic background Interstitial lung disease (ILD) is defined by an inflammatory, often fibrotic, and diffuse process, predominant in the pulmonary interstitium. Idiopathic pulmonary fibrosis (IPF) is one of the most common chronic idiopathic fibrotic interstitial lung disease. IPF is an scalable disease that requires regular follow-up through clinical examination and respiratory functional investigations. A thoracic CT scan is usually performed annually in the absence of exacerbation. CT scan is essential for initial diagnosis and follow-up, especially in case of deterioration of respiratory function. The main disadvantages to its realization are the repeated irradiation, the cost, the accessibility, and sometimes the difficulties of realization related to the supine position and the maintenance of a prolonged apnea in patients with severe dyspnea.

For several years, the semiology of interstitial lung diseases has been enriched by the description of several signs of thoracic ultrasound, including the number of B lines, the irregularity of the pleural line, and the thickening of the pleural line. Several cross-sectional studies have correlated the intensity of these signs with the severity of fibrosis lesions on chest CT in patients with ILD, including IPF. However, no studies have prospectively described the evolution of ultrasound signs in the same IPF patient, or their correlation to clinical, functional and CT evolution.

The hypothesis is that thoracic ultrasound is a relevant tool to highlight the evolution of pulmonary lesions in IPF.

  • Objective of the study: The main objective is to show with thoracic ultrasound an increase in one or more of the ultrasound signs: line B score, pleural line irregularity score, and pleural line thickness during the follow-up of patient with IPF. The secondary objectives are to evaluate the reproducibility of the measurements of the pulmonary ultrasound signs, to evaluate the association between the severity of each pulmonary ultrasound sign and the severity of the clinical, functional and CT scores and to evaluate the association between the measurement of each ultrasound sign made during a standard protocol exploring 14 intercostal spaces and a simplified protocol exploring 6 intercostal spaces.
  • Design: This is a prospective, multicenter, non-interventional, prospective study evaluating patients followed for IPF at the University Hospital of Tours and the Hospital of Orléans, France.

Number of participants: 30

  • Interventions and analysis: The study will enroll patients with a validated diagnosis of IPF in a multidisciplinary staff. For each patient included, study duration will be 12 months. At each follow-up visit, patients will have a clinical examination, pulmonary functional test and thoracic ultrasound. The CT data collected will include the last thoracic CT performed in the 3 months before the inclusion and those performed during the patient's participation.

Thoracic ultrasonography will be performed on D0, M3, M6, M9 and M12. It will occur during the follow-up consultation carried out as part of usual care. Thus, inclusion in the study does not change the usual rhythm of consultations or complementary examinations (pulmonary functional tests and thoracic CT scan) in the care of the patient.

A convex probe (1 to 5 MHz) will be used. The patient will be placed in right lateral decubitus then left. Thoracic ultrasonography will be timed, recorded and anonymized. It will be practiced by experienced operators and according to a validated protocol allowing the exploration of 14 intercostal spaces. The recording loops will be read over later by the operator himself and then by a second operator to evaluate the intra- and inter-operator variability respectively.

The presence, location and severity of ultrasound signs, will be recorded for each patient during successive reassessments and correlation to clinical, functional and CT scan evolution will be made.

Being tested
Lung ultrasound
Keywords
Lung ultrasound, B lines, Pleural irregularity
Medical subject headings
Idiopathic Pulmonary Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lung ultrasoundOther

    For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.

    For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.

    The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of the B-line score from inclusion to 12 months

    number of line

    Measured: Inclusion, 12 months

  2. Change of pleural line irregularity from inclusion to 12 months

    Percentage

    Measured: Inclusion, 12 months

  3. Change of pleural line thickness from inclusion to 12 months

    in millimeters

    Measured: Inclusion, 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2019
  2. Study start11 Jun 2019
  3. Primary completion3 Aug 2020
  4. Study completion9 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03944928
Sponsor's protocol ID
RIPH3-RNI19-TOUPIE
Acronym
TOUPIE
Status last verified
Oct 2021
First submitted
3 May 2019
Last updated
5 Oct 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Legue S, Marchand-Adam S, Plantier L, Bayeh BA, Morel H, Mangiapan G, Flament T. ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open. 2021 Mar 25;11(3):e039078. doi: 10.1136/bmjopen-2020-039078.

    PubMed 33766834

Questions about this trial

What is this clinical trial studying?

An observational study of Idiopathic Pulmonary Fibrosis, run by University Hospital, Tours at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of the B-line score from inclusion to 12 months (time frame: Inclusion, 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03944928, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in